| June 8, 2011 |
Daiichi Sankyo Launches Memary(R) 5mg, 10mg and 20mg Tablets for the Treatment of Alzheimer’s Disease in Japan(Daiichi-Sankyo briefing paper, June 8). |
| January 21,2011 |
Acquisition of approval for production and sale of "Memary (R) tablet", an NMDA receptor antagonism Alzheimer-type dementia therapeutic agent(Daiichi-Sankyo briefing paper, January 21). |
| February 8,2010 |
Announcement of Approval Application in Japan for Manufacturing and Marketing of SUN Y7017 (Memantine) for the Treatment of Alzheimer's Type Dementia |
| March 16,2009 |
Daiichi Sankyo Announces Restructuring and Relocation of Subsidiary |
| July 16,2008 |
Asubio Pharma's Inherited Metabolic Disease Agent Biopten Receives Approval for Additional Indication |
| December 17,2007 |
Asubio Pharma's Congenital Metabolic Abnormalities Agent Biopten Approved by U.S. Food and Drug Administration for Treatment of BH4 Responsive Hyperphenylalaninemia |
